Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| ras Proteins | 13 | 2021 | 134 | 3.780 |
Why?
|
| Cell Membrane | 11 | 2020 | 687 | 3.140 |
Why?
|
| Molecular Dynamics Simulation | 10 | 2019 | 308 | 2.020 |
Why?
|
| Lipid Bilayers | 5 | 2021 | 147 | 1.700 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 6 | 2019 | 180 | 1.550 |
Why?
|
| Protein Conformation | 6 | 2019 | 935 | 0.820 |
Why?
|
| Thoracostomy | 1 | 2020 | 10 | 0.660 |
Why?
|
| Hemothorax | 1 | 2020 | 13 | 0.660 |
Why?
|
| Chest Tubes | 1 | 2020 | 21 | 0.660 |
Why?
|
| Thoracic Injuries | 1 | 2020 | 41 | 0.640 |
Why?
|
| Genes, ras | 2 | 2018 | 97 | 0.610 |
Why?
|
| Protein Kinases | 1 | 2020 | 216 | 0.590 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2019 | 50 | 0.590 |
Why?
|
| Protein Domains | 2 | 2019 | 164 | 0.590 |
Why?
|
| Protein Multimerization | 2 | 2017 | 196 | 0.580 |
Why?
|
| Catalytic Domain | 5 | 2020 | 165 | 0.560 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2016 | 18 | 0.490 |
Why?
|
| Neutrophils | 2 | 2017 | 326 | 0.450 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 220 | 0.450 |
Why?
|
| Models, Chemical | 1 | 2015 | 187 | 0.440 |
Why?
|
| Protein Binding | 6 | 2017 | 1560 | 0.410 |
Why?
|
| Computational Biology | 3 | 2017 | 587 | 0.400 |
Why?
|
| Cholic Acid | 1 | 2012 | 8 | 0.380 |
Why?
|
| Phosphorylcholine | 1 | 2012 | 27 | 0.370 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 13 | 0.370 |
Why?
|
| Ibuprofen | 1 | 2012 | 33 | 0.370 |
Why?
|
| Micelles | 1 | 2012 | 53 | 0.370 |
Why?
|
| Phagocytosis | 1 | 2012 | 111 | 0.360 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 355 | 0.350 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 684 | 0.350 |
Why?
|
| Trauma Centers | 3 | 2021 | 174 | 0.340 |
Why?
|
| Binding Sites | 4 | 2020 | 1167 | 0.330 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 249 | 0.320 |
Why?
|
| Lymphangitis | 1 | 2010 | 1 | 0.320 |
Why?
|
| Phosphatidylserines | 2 | 2021 | 21 | 0.320 |
Why?
|
| Mutation | 3 | 2019 | 4374 | 0.300 |
Why?
|
| Phosphorylation | 3 | 2020 | 1156 | 0.280 |
Why?
|
| Sepsis | 1 | 2012 | 389 | 0.270 |
Why?
|
| Mutation, Missense | 2 | 2019 | 302 | 0.260 |
Why?
|
| Guanosine Triphosphate | 3 | 2017 | 38 | 0.250 |
Why?
|
| Humans | 27 | 2021 | 95992 | 0.250 |
Why?
|
| Carcinoma | 1 | 2010 | 444 | 0.250 |
Why?
|
| Ligands | 4 | 2017 | 478 | 0.240 |
Why?
|
| Models, Molecular | 4 | 2017 | 1376 | 0.230 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 2384 | 0.180 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2021 | 10 | 0.180 |
Why?
|
| Intestinal Perforation | 1 | 2021 | 39 | 0.180 |
Why?
|
| Prenylation | 1 | 2021 | 3 | 0.170 |
Why?
|
| Logistic Models | 3 | 2020 | 1273 | 0.170 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2013 | 150 | 0.160 |
Why?
|
| Cell Line | 3 | 2021 | 2536 | 0.160 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 142 | 0.160 |
Why?
|
| Injury Severity Score | 1 | 2020 | 154 | 0.160 |
Why?
|
| Drainage | 1 | 2020 | 172 | 0.150 |
Why?
|
| Thrombectomy | 1 | 2021 | 220 | 0.150 |
Why?
|
| Wounds, Gunshot | 1 | 2021 | 121 | 0.150 |
Why?
|
| Single Molecule Imaging | 1 | 2018 | 16 | 0.150 |
Why?
|
| Pneumonia | 1 | 2020 | 196 | 0.140 |
Why?
|
| Phosphatidylcholines | 1 | 2018 | 50 | 0.140 |
Why?
|
| Cricetulus | 1 | 2018 | 132 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2021 | 258 | 0.140 |
Why?
|
| Firearms | 1 | 2019 | 79 | 0.140 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2018 | 101 | 0.140 |
Why?
|
| Stents | 1 | 2021 | 422 | 0.140 |
Why?
|
| Cricetinae | 1 | 2018 | 542 | 0.140 |
Why?
|
| Thoracotomy | 1 | 2018 | 68 | 0.140 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1018 | 0.140 |
Why?
|
| Protein Isoforms | 1 | 2019 | 296 | 0.140 |
Why?
|
| Nanostructures | 1 | 2018 | 89 | 0.140 |
Why?
|
| Leukocyte Count | 1 | 2017 | 217 | 0.130 |
Why?
|
| Occupational Exposure | 1 | 2018 | 89 | 0.130 |
Why?
|
| Cyclic GMP-Dependent Protein Kinase Type II | 1 | 2016 | 2 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2777 | 0.130 |
Why?
|
| Length of Stay | 1 | 2020 | 835 | 0.130 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2017 | 91 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2016 | 85 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 491 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2385 | 0.120 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2016 | 72 | 0.120 |
Why?
|
| Anions | 1 | 2016 | 31 | 0.120 |
Why?
|
| Allosteric Site | 2 | 2015 | 23 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 655 | 0.120 |
Why?
|
| Amino Acid Sequence | 2 | 2017 | 2090 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2017 | 295 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2017 | 465 | 0.120 |
Why?
|
| Algorithms | 2 | 2015 | 2018 | 0.110 |
Why?
|
| Adult | 7 | 2020 | 28636 | 0.110 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 81 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 492 | 0.110 |
Why?
|
| Molecular Probes | 1 | 2015 | 37 | 0.110 |
Why?
|
| Software | 2 | 2015 | 698 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2020 | 4690 | 0.110 |
Why?
|
| Middle Aged | 6 | 2020 | 28299 | 0.110 |
Why?
|
| Mutant Proteins | 3 | 2021 | 99 | 0.100 |
Why?
|
| Animals | 5 | 2021 | 28901 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 342 | 0.100 |
Why?
|
| Critical Illness | 2 | 2017 | 346 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 593 | 0.100 |
Why?
|
| Solutions | 1 | 2013 | 86 | 0.100 |
Why?
|
| Male | 8 | 2021 | 45792 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 2498 | 0.100 |
Why?
|
| United States | 3 | 2020 | 7785 | 0.100 |
Why?
|
| Peritoneal Lavage | 1 | 2012 | 12 | 0.090 |
Why?
|
| Sampling Studies | 1 | 2012 | 76 | 0.090 |
Why?
|
| Physicians | 1 | 2019 | 707 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 1 | 2012 | 267 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2012 | 64 | 0.090 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 233 | 0.090 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2012 | 133 | 0.090 |
Why?
|
| Bile Acids and Salts | 1 | 2012 | 77 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 115 | 0.090 |
Why?
|
| Nucleotides | 1 | 2012 | 99 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 2012 | 148 | 0.090 |
Why?
|
| Computer Simulation | 2 | 2015 | 1158 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 325 | 0.090 |
Why?
|
| Reference Values | 1 | 2012 | 675 | 0.090 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2011 | 26 | 0.080 |
Why?
|
| Urinary Catheterization | 1 | 2011 | 40 | 0.080 |
Why?
|
| Flow Cytometry | 1 | 2012 | 725 | 0.080 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2011 | 30 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2012 | 909 | 0.080 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 527 | 0.080 |
Why?
|
| Water | 1 | 2012 | 307 | 0.080 |
Why?
|
| Iopamidol | 1 | 2010 | 10 | 0.080 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 155 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2012 | 936 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2018 | 3581 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2020 | 9228 | 0.070 |
Why?
|
| Female | 7 | 2020 | 49980 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 207 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2012 | 594 | 0.070 |
Why?
|
| Radiography | 1 | 2010 | 823 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 1144 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 2042 | 0.070 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2928 | 0.060 |
Why?
|
| Inflammation | 1 | 2012 | 1063 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 800 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1464 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 7224 | 0.060 |
Why?
|
| Heart Failure | 1 | 2016 | 1438 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 2042 | 0.060 |
Why?
|
| Neoplasms | 2 | 2019 | 3242 | 0.060 |
Why?
|
| Contrast Media | 1 | 2010 | 1097 | 0.050 |
Why?
|
| Lipids | 2 | 2016 | 285 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2017 | 485 | 0.050 |
Why?
|
| Gastroenterostomy | 1 | 2021 | 7 | 0.050 |
Why?
|
| Endosonography | 1 | 2021 | 101 | 0.040 |
Why?
|
| Static Electricity | 1 | 2021 | 97 | 0.040 |
Why?
|
| Politics | 1 | 2019 | 53 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 166 | 0.040 |
Why?
|
| Aged | 3 | 2016 | 20927 | 0.040 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2019 | 66 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 84 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 367 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2021 | 198 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 640 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 336 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 102 | 0.030 |
Why?
|
| Health Surveys | 1 | 2018 | 245 | 0.030 |
Why?
|
| Neoprene | 1 | 2016 | 1 | 0.030 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2016 | 23 | 0.030 |
Why?
|
| Sildenafil Citrate | 1 | 2016 | 24 | 0.030 |
Why?
|
| Serine | 1 | 2016 | 108 | 0.030 |
Why?
|
| Hominidae | 1 | 2017 | 106 | 0.030 |
Why?
|
| Chicago | 1 | 2021 | 1505 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 241 | 0.030 |
Why?
|
| Endocytosis | 1 | 2016 | 186 | 0.030 |
Why?
|
| Dogs | 1 | 2016 | 718 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2015 | 58 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 890 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2016 | 281 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 799 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 82 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 905 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 118 | 0.030 |
Why?
|
| Adolescent | 2 | 2021 | 9878 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1347 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1931 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1753 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2776 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2017 | 10307 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 946 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 3993 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 435 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2011 | 378 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5992 | 0.020 |
Why?
|